and its congener 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl}guanine (BW B759U) exhibit comparable antiviral activity against . However, BW B759U is a more potent inhibitor of both human CMV and Epstein-Barr virus (EBV) in vitro than is ACV (1-3, 5). As is the case with ACV, BW B759U is activated to the triphosphate form in HSV-and VZV-infected cells and the initial step of this phosphorylation is associated with the activity of the virus-specified thymidine kinase (TK) (refs. 4, 6-8; unpublished data Table 1 ). In the present study, we report that BW B759U, in contrast to ACV, is preferentially activated in human diploid fibroblasts infected with HCMV.
100-fold higher than the levels found in uninfected cells. BW B759U-triphosphate accumulated in HCMV-infected cells with time; the rate of this increase was dependent upon the drug dose and virus multiplicity of infection. Enzyme activities that catalyzed the phosphorylation of thymidine and 2'-deoxycytidine increased 3-to 7-fold in extracts of cells early after HCMV infection but thereafter declined. No concomitant increase in the rate of BW B759U phosphorylation was detected under these assay conditions. Maximal rate of accumulation of both BW B759U-triphosphate and ACV-triphosphate after a short exposure to drug occurred in the late phase of the infective cycle, as the titer of extracellular virus reached a peak in untreated cultures, but after the decline of stimulated host deoxypyrimidine kinase activities. Once formed, the BW B759U-triphosphate pool decreased very slowly and thus it persisted for several days in both HCMV-infected and uninfected cells.
The therapy of herpesvirus infections has recently advanced with the development of nucleoside analogs that are active only in the herpesvirus-infected cells. This selectivity appears to depend upon several factors: the level of nucleoside activation in the infected cell, the competing intracellular deoxynucleoside triphosphate pools, and the relative sensitivity of the target enzyme, viral DNA polymerase. With herpes simplex virus (HSV) or varicella zoster virus (VZV), specific phosphorylation of most of the antiviral nucleoside analogs is initiated by the virus-encoded deoxypyrimidine kinases. The anti-herpes nucleoside analog acyclovir (ACV) and its congener 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl}guanine (BW B759U) exhibit comparable antiviral activity against HSV and VZV in vitro (1) (2) (3) (4) (5) . However, BW B759U is a more potent inhibitor of both human CMV and Epstein-Barr virus (EBV) in vitro than is ACV (1) (2) (3) 5) . As is the case with ACV, BW B759U is activated to the triphosphate form in HSV-and VZV-infected cells and the initial step of this phosphorylation is associated with the activity of the virus-specified thymidine kinase (TK) (refs. 4, 6-8; unpublished data). TK-deficient mutants of HSV and VZV are resistant in vitro to both ACV and BW B759U (refs. 1-3; unpublished data).
Human cytomegalovirus (HCMV), on the other hand, reportedly does not induce such a novel TK activity in infected cells (9, 10 ), yet HCMV is susceptible to inhibition by at least two nucleoside analogs, 2'-fluoro-5-iodoarabinosylcy- Table 1 ). In the present study, we report that BW B759U, in contrast to ACV, is preferentially activated in human diploid fibroblasts infected with HCMV.
MATERIALS AND METHODS
Cells and Virus. Human foreskin fibroblast (HFF) cells were derived in this laboratory from tissues obtained from Duke University Hospital Pediatrics Department (Durham, NC) and were used up to passage 11. Human diploid embryonic lung fibroblast (MRC-5) cells were obtained from American Type Culture Collection and were used between passage 22 and passage 26. Monolayer cultures were grown in Eagle's minimal essential medium (ME medium) containing 50 units of penicillin per ml and 50 ,g of streptomycin per ml supplemented with 10% fetal bovine serum (Sterile Systems, Logan, Utah) and 1% L-glutamine. HCMV strain AD169 was also obtained from American Type Culture Collection. Kerr strain of HCMV was obtained from E. S. Huang (Cancer Research Center, University of North Carolina, Chapel Hill). The clinical strain Wade was isolated. from a congenitally infected infant by J. Zeller (Duke University Hospital Infectious Diseases Laboratory).
Virus stocks of AD169 were stored in liquid nitrogen and were amplified before use by low multiplicity of infection (moi) passage in MRC-5 cells [<0.05 plaque-forming units (pfu) per cell]. Supernatant virus was used at time of peak titer (days 8-11) and was back titrated at the time of use to determine approximate moi.
Cells and virus stocks were routinely checked for mycoplasma contamination by electron microscopy and [125i]iododeoxycytidine autoradiography methods.
Cell Cytotoxicity Assay. The cytotoxicity of the nucleoside analogs was determined by Naomi Cohn (The Wellcome Research Laboratories) by using a cell growth assay that allows DNA Polymerase Purification and Assay. The virus-specific DNA polymerase was partially purified from extracts of AD169-infected MRC-5 cells by sequential ion-exchange chromatography on DEAE-cellulose (Whatman DE52) and cellulose phosphate (Whatman P11) as described (5). Polymerase activity was measured by using the optimal synthetic template primer poly(dC)-oligo(dG) in the presence of 60 mM ammonium sulfate (5) . Kinetic constants were determined by the use of the computer program of Cleland (13) and enzyme inhibition was analyzed according to the method of Spector and Hajian (14) .
Enzyme Assays. Cytosol extracts of cells were prepared as described (15) and desalted before use. Reaction mixtures to measure phosphorylation of 2'-deoxycytidine (16) contained the following: 6 mM ATP, 6 mM MgCl2, 0.2% (wt/vol) bovine serum albumin, 10 units of creatine kinase per ml, 6 mM creatine phosphate, 100 mM Tris HCl (pH 7.5), 2 mM dithiothreitol, and 0.3 mM 2'-deoxy[2-14C]cytidine (14 cpm/pmol, Moravek Biochemicals, City of Industry, CA). The reaction mixtures with thymidine (2'-deoxyribosylthymine) as phosphate acceptor were the same, except 2 mM ATP, 2 mM MgCl2, 1.0% bovine serum albumin, and 0.1 mM [2-'4C]thymidine (53 cpm/pmol, ICN) were used. Identical sets of reaction mixtures for measuring the phosphorylation of BW B759U contained 2 mM [8-14C]BW B759U (74 cpm/pmol) in place of deoxycytidine or thymidine. The deoxycytidine and thymidine reaction mixtures were spotted onto DEAE paper, washed, dried, and assayed for radioactivity (15) . Reactions containing BW B759U were stopped by mixing 10-,ul samples into 0.5 ml of 0.1 M HCl and analyzing with cationexchange columns as described (17) . All rates of phosphorylation were constant during the 60-min assay time. Protein concentrations were estimated by the Coomassie brilliant blue dye method (18) .
ACV was chemically synthesized at The Wellcome Research Laboratories by published procedures (19) Table 1 ). The compound is highly effective at concentrations below the cytotoxic level for human diploid fibroblasts.
Inhibition of HCMV DNA Polymerase by the Triphosphates of BW B759U and ACV. The kinetics of inhibition of the partially purified HCMV DNA polymerase were studied (5 (Table 2) . Under these experimental conditions, appreciable levels of BW B759U-triphosphate were not apparent before 48 hr postinfection. The low levels of BW B759U-triphosphate initially measured in uninfected cells declined despite continued incubation of uninfected HFF cells in the presence of BW B759U.
In a similar experiment with ACV, the formation of ACVtriphosphate after HCMV infection was compared to that of BW B759U-triphosphate in MRC-5 cells. Cells were either mock-infected or infected with AD169, radiolabeled compounds were added at 26 hr postinfection, and samples were then harvested at the indicated times (Fig. 1) formation of BW B759U-triphosphate was observed in HCMV-infected cells (Fig. 3) .
Relative Rate of BW B759U Phosphorylation in Uninfected and HCMV-Infected Cells. The relative rate of triphosphate formation was assessed throughout the virus replication cycle by pulse-labeling experiments, and this activity was related to several known parameters of the infectious cycle. These parameters included the generation of extracellular infectious virus as well as the induction of host deoxycytidine and thymidine phosphorylation activities. HCMV infection of cells has been shown to stimulate the levels of cytosol TK and deoxycytidine kinase (9, 10 (Fig. 4b) . These activities peaked on day 3 postinfection, well before the phosphorylation of BW B759U and ACV reached a maximum under the conditions of this experiment (Fig. 4c) . [14C]BW B759U was added for 24 hr. One sample was harvested for determination of BW B759U-triphosphate (BW B759U-TP) levels. The remaining samples were washed to remove residual radiolabeled drug, and one half of the samples were refed medium containing 50 btM unlabeled BW B759U. The other half received medium with no addition. At various times after drug removal, samples were harvested and BW B759U-triphosphate levels were measured by HPLC analysis.
identical design but with an moi lower by a factor 5, confirmed the time differential between the induced host deoxycytidine kinase and TK activities and maximal rate of phosphorylation of BW B759U (data not shown). This difference is clearly demonstrated by a plot of the ratio of host TK activity to levels of BW B759U-triphosphate in the two separate experiments (Fig. 4c) .
Phosphorylation of BW B759U was also examined in these same extracts of uninfected and HCMV-infected MRC-5 cells. Under conditions optimal for assay of either host deoxycytidine kinase or TK, no significant differences were seen between infected and uninfected extracts, regardless of time after infection. The thymidine phosphorylating activity was partially purified from cytosol extracts of rapidly growing MRC-5 cells. As was true with purified TK from Vero cells (unpublished data), no phosphorylation of BW B759U was detected with this partially purified host cell TK (<3% of the rate of thymidine phosphorylation).
Persistence Proc. NatL Acad Sci. USA 82 (1985) A sensitivity of the HCMV DNA polymerase to competitive inhibition by the triphosphates of these two nucleoside analogs (ref. 5; Table 1 ). Data presented in this communication suggest that one major difference in the sensitivity of HCMV to BW B759U and ACV resides in the ability of the infected cell to preferentially generate high levels of the triphosphate of BW B759U. The triphosphate of BW B759U, once formed, appears quite stable and persists for days in the HCMV-infected cell. This is in contrast to the shorter halflife measured for ACV-triphosphate in the HSV-infected cell (24) . The addition of an unlabeled extracellular pool of BW B759U to the cells had no significant effect on the slow rate of loss of [14C]BW B759U-triphosphate from the cells. In the case in which the replacement medium contained unlabeled BW B759U, the triphosphate continued to accumulate, although the 14C-labeled component decreased at a rate that was insensitive to the presence of an unlabeled pool of BW B759U.
The uninfected cell is also capable of producing low levels of BW B759U-triphosphate, but at low levels detectable only with radiolabeled drug. The triphosphate form, however, does not accumulate in the uninfected cell, and the transient increase detected after initial exposure of newly seeded cultures to the compound disappeared upon continued incubation. ACV-triphosphate levels, on the other hand, were not detectable in these uninfected cells even with radiolabeled compound.
The identification of the enzyme(s) responsible for the phosphorylation of BW B759U remains to be determined. The uninfected cell contains an activity (or activities) capable of phosphorylating BW B759U, although the efficiency is low. Infection of these cells with HCMV results in the appearance of elevated levels of BW B759U-triphosphate. The kinetics of induction of the BW B759U phosphorylating activity (or activities) are clearly quite different from those measured for the induction of host cytosol deoxycytidine kinase and TK activities under the experimental conditions described here (Fig. 4) . The induced BW B759U phosphorylating activity reached a maximum in the untreated infected cells later in the infection cycle, after the induced host activities had declined and coincident with high titers of extracellular virus (Fig. 4) . Furthermore, the amounts of BW B759U-triphosphate formed during a short drug pulse late in infection were higher than those measured when drug was added early after virus infection and maintained continuously until time of harvest late in the infection cycle. (Figs. 2 and 4) . This may be a result of unrestricted viral DNA synthesis prior to drug treatment, causing amplification of the infection within either the individually infected cells or within the total cell population.
It has recently been demonstrated that BW B759U is a more potent inhibitor of HCMV DNA synthesis in the infected, drug-treated cell than is ACV (25, 26) . The data presented here indicate that although BW B759U-triphosphate is somewhat less effective an inhibitor than is ACV-triphosphate for the HCMV DNA polymerase, this compound is more efficiently activated in the HCMV-infected cell to provide levels of BW B759U-triphosphate up to 30-fold higher than those measured for ACV-triphosphate. These 
